Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBT6290 + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SBT6290 + pembrolizumab is an investigational combination therapy for cancer composed of SBT6290, a targeted immunocytokine, and pembrolizumab, an anti–PD-1 monoclonal antibody. **SBT6290** is an engineered immunocytokine designed to selectively deliver interleukin-2 (IL-2) to tumors expressing Nectin-4, aiming to enhance antitumor immune responses while limiting systemic toxicity. **Pembrolizumab (Keytruda)** is a humanized monoclonal IgG4 antibody that blocks the programmed cell death protein 1 (PD-1) receptor on T-cells, overcoming inhibitory signaling from tumor cell PD-L1/PD-L2 and enabling an improved immune response against tumors[2][4][6]. The combination is being developed for advanced solid tumors to harness synergistic immunostimulatory effects.
- Other names
- MK-3475MK3475MK 3475SCH 900475SCH900475SCH-900475SBT6290 + Keytruda
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)PDCD1 (Programmed cell death protein 1 receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on SBT6290 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBT6290 + pembrolizumab.